{'fraction_non_alphanumeric': 0.034787410270568746, 'fraction_numerical': 0.01932633903920486, 'mean_word_length': 5.4714285714285715, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.

Sixty-four patients underwent 66 remission induction courses with intermediate-dose cytosine-arabinoside (Ara-C) for treatment of acute myelogenous leukemia, acute lymphoblastic leukemia, or high-grade malignant non-Hodgkin's lymphoma. The Ara-C was administered in combination with amsacrine with or without VP16-213 and prednisone. After complete remission was achieved, 27 patients received 38 consolidation courses consisting of high-dose Ara-C either alone or in combination with amsacrine with or without VP16-213 and prednisone. Seven (11%) of 66 induction courses and eight (21%) of 38 consolidation courses were complicated by respiratory failure that was considered a pulmonary reaction to Ara-C therapy. The initial findings on chest radiographs in the 15 cases included a diffuse interstitial pattern (two), a mixed interstitial-alveolar pattern (eight), an alveolar pattern (three), and a normal pattern (two). In 11 cases, the abnormalities were diffuse throughout both lungs with a preference for the lower lobes in five. The changes were localized in two cases. A small pleural effusion was observed in two patients. In the majority of cases, the initial radiographic changes progressed to a predominantly alveolar pattern. Thirteen patients recovered clinically within 2-9 days, and two patients died of pulmonary complications. Radiologic recovery took 7-21 days. Rapid regression of alveolar consolidations within 3-7 days was the first sign of radiologic improvement. The interstitial pattern gradually regressed. We conclude that the spectrum of radiologic abnormalities in cases of pulmonary reaction to Ara-C therapy includes diffuse interstitial, mixed interstitial-alveolar, or alveolar pulmonary changes.